ResearcherUniversity of California San DiegoActive in the last 2 years
Yutaro Kubota
Matched on ORCID iD 0000-0002-2917-8764; OpenAlex author ID A5003522731. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper
Papers 8
- Precise Non-invasive Imaging Mouse Model of Pancreatic Cancer: Very Narrow Band-width Laser Fluorescence Excitation of Green Fluorescent Protein Provides Ultra… Co-author DOI 10.21873/cdp.10281↗
- Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease. Co-author DOI 10.21873/anticanres.15734↗
- The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000001731↗
- High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer. Co-author DOI 10.3892/ijo.2020.5147↗
- High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0226707↗
- High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer. Co-author DOI 10.3892/or.2020.7610↗
- Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX. Co-author DOI 10.18632/oncotarget.12007↗
- Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer? Co-author DOI 10.1111/cas.12708↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Robert M. Hoffman · 2 shared papers, 2022–2024 · strength 0.37
- Paper Precise Non-invasive Imaging Mouse Model of Pancreatic Cancer: Very Narrow Band-width Laser Fluorescence Excitation of … DOI 10.21873/cdp.10281↗
- Paper Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Lon… DOI 10.21873/anticanres.15734↗
- Satoshi Wada · 4 shared papers, 2020–2021 · strength 0.36
- Paper The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable… DOI 10.1097/mpa.0000000000001731↗
- Paper High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor pr… DOI 10.3892/ijo.2020.5147↗
- Paper High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in p… DOI 10.3892/or.2020.7610↗
- Ryotaro Ohkuma · 4 shared papers, 2020–2021 · strength 0.36
- Paper The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable… DOI 10.1097/mpa.0000000000001731↗
- Paper High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor pr… DOI 10.3892/ijo.2020.5147↗
- Paper High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in p… DOI 10.3892/or.2020.7610↗
- Erica Yada · 3 shared papers, 2020–2021 · strength 0.25
- Paper High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor pr… DOI 10.3892/ijo.2020.5147↗
- Paper High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in p… DOI 10.3892/or.2020.7610↗
- Paper High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer. DOI 10.1371/journal.pone.0226707↗
- Tetsuro Sasada · 3 shared papers, 2020–2021 · strength 0.25
- Paper High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor pr… DOI 10.3892/ijo.2020.5147↗
- Paper High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in p… DOI 10.3892/or.2020.7610↗
- Paper High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer. DOI 10.1371/journal.pone.0226707↗
- Tomoko Norose · 3 shared papers, 2020–2021 · strength 0.25
- Paper High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor pr… DOI 10.3892/ijo.2020.5147↗
- Paper High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in p… DOI 10.3892/or.2020.7610↗
- Paper High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer. DOI 10.1371/journal.pone.0226707↗
- Sei Morinaga · 1 shared paper, 2024 · strength 0.20
- Jun Yamamoto · 1 shared paper, 2022 · strength 0.16
- Wataru Ichikawa · 2 shared papers, 2015–2016 · strength 0.10
- Paper Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic ca… DOI 10.1111/cas.12708↗
- Paper Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOL… DOI 10.18632/oncotarget.12007↗
- Yasutsuna Sasaki · 2 shared papers, 2015–2016 · strength 0.10
- Paper Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic ca… DOI 10.1111/cas.12708↗
- Paper Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOL… DOI 10.18632/oncotarget.12007↗
- Koji Tamada · 1 shared paper, 2020 · strength 0.08
- Takehiko Yokobori · 1 shared paper, 2020 · strength 0.08
- Yasuhiro Kaga · 1 shared paper, 2016 · strength 0.05
- Yu Sunakawa · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.